Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 661 to 670 of 1113 total matches.
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
of CYP
substrates administered concurrently.4
PREGNANCY AND LACTATION ― No adequate data
are available ...
Tarlatamab-dlle (Imdelltra – Amgen), a first-in-class
bispecific delta-like ligand 3 (DLL3)-directed CD3
T-cell engager, has received accelerated approval
from the FDA for treatment of extensive-stage
small cell lung cancer (SCLC) in adults who had
disease progression on or after platinum-based
chemotherapy. It is the first bispecific DLL3-directed
CD3 T-cell engager to be approved in the US for this
indication. Most patients with SCLC have a response
to initial treatment, but progression generally
occurs within a few months and overall survival is
usually less than 8 months....
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e113-4 doi:10.58347/tml.2024.1706c | Show Introduction Hide Introduction
Iloprost (Aurlumyn) for Frostbite
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
typically includes analgesia and rewarming of the affected area. High-quality data on treatment of severe ...
The FDA has approved Aurlumyn (Eicos Sciences),
an IV formulation of the prostacyclin analog iloprost,
to reduce the risk of digit amputation in adults
with severe frostbite. Iloprost is the first drug to be
approved by the FDA for treatment of severe frostbite;
it has been used off-label for this indication in the EU
and elsewhere for decades. In the US, iloprost is also
available as an inhaled formulation (Ventavis) for
treatment of pulmonary arterial hypertension.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):114 doi:10.58347/tml.2024.1707b | Show Introduction Hide Introduction
Roflumilast Cream (Zoryve) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
patients;
data on its efficacy and safety with long-term use are
lacking.6
MECHANISM OF ACTION ...
The FDA has approved a 0.15% cream formulation
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate atopic dermatitis (AD) in patients
≥6 years old. Roflumilast is the second PDE4 inhibitor
to be approved in the US for treatment of AD;
crisaborole (Eucrisa), which can be used in patients
≥3 months old, was the first. Roflumilast is available
as Zoryve in a 0.3% cream for treatment of plaque
psoriasis and a 0.3% foam for treatment of seborrheic
dermatitis. It is also available in an oral formulation
(Daliresp) for...
Med Lett Drugs Ther. 2024 Sep 16;66(1711):150-1 doi:10.58347/tml.2024.1711b | Show Introduction Hide Introduction
Adagrasib (Krazati) for Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
and reduced fetal
weight. No data on the presence of adagrasib in
breast milk or its effect on the breastfed ...
The RAS GTPase family inhibitor adagrasib (Krazati –
BMS), which received accelerated approval for
treatment of KRAS G12C (glycine-to-cysteine mutation
at codon 12)-mutated locally advanced or metastatic
non-small cell lung cancer (NSCLC) in 2022, has now
received accelerated approval from the FDA for use
with cetuximab for treatment of KRAS G12C-mutated
locally advanced or metastatic colorectal cancer
(CRC) in adults who received prior fluoropyrimidine-,
oxaliplatin-, and irinotecan-based chemotherapy.
Adagrasib is the first KRAS inhibitor to be approved in
the US for treatment...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e137-8 doi:10.58347/tml.2024.1709f | Show Introduction Hide Introduction
In Brief: One Drop or Two
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
. Cost for 30 days' treatment, based on most recent data (April 30, 2006) from retail pharmacies ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Treatment of Clostridium difficile-Associated Disease (CDAD)
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006 (Issue 1247)
to bacterial resistance to metronidazole.
Data on failure rates with vancomycin in patients
infected ...
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile-associated disease (CDAD).
Two New Drugs for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
AND LACTATION — Systemic exposure
from ophthalmic drugs is expected to be low. There are
no data on the use ...
The FDA has approved two new ophthalmic drugs for
reduction of intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension: latanoprostene
bunod (Vyzulta – Bausch and Lomb), a modified
prostaglandin analog, and netarsudil (VRhopressa – Aerie),
the first Rho kinase inhibitor to be approved in the US.
Daridorexant (Quviviq) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
vs placebo.
1. E Mignot et al. Lancet Neurol 2022; 21:125. 2. Data presented as mean values. 3. Also ...
The FDA has approved daridorexant (Quviviq –
Idorsia), an orexin receptor antagonist, for treatment
of sleep-onset and/or sleep-maintenance insomnia
in adults. Daridorexant is the third orexin receptor
antagonist to be approved for this indication;
suvorexant (Belsomra) and lemborexant (Dayvigo)
were approved earlier.
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
to reduce sunburn and improve signs of
photodamage in humans, but data are limited and
none ...
In June 2021, the FDA approved the IV amyloid beta-directed
monoclonal antibody aducanumab (Aduhelm) for treatment
of Alzheimer’s disease. The approval did not restrict use of
the drug to patients with mild cognitive impairment or mild
dementia, which was the population enrolled in the clinical
trials. Now, Biogen, with the permission of the FDA, has made
an addition to the labeling of the drug that says: Treatment with
Aduhelm should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease, the population
in which treatment was initiated in clinical...
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
infection during pregnancy has not been
associated with adverse maternal or fetal outcomes,
but data ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction